Brainstorm Cell Therapeutics Inc (BCLI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Brainstorm Cell Therapeutics Inc (BCLI) has a cash flow conversion efficiency ratio of 0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.32 Million) by net assets ($-11.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Brainstorm Cell Therapeutics Inc (BCLI) balance sheet quality index to measure how much of total assets are equity-financed.
Brainstorm Cell Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Brainstorm Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Brainstorm Cell Therapeutics Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Brainstorm Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brainstorm Cell Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Newbury Pharmaceuticals AB
ST:NEWBRY
|
0.072x |
|
Youxin Technology Ltd Class A Ordinary shares
NASDAQ:YAAS
|
-0.202x |
|
Perpetual Resources Ltd
AU:PEC
|
-0.164x |
|
EBANG INTL HLDGS (NEW) A
F:7EBA
|
N/A |
|
Chia Yi Steel Co Ltd
TWO:2067
|
-0.113x |
|
Discoverie Group PLC
LSE:DSCV
|
0.070x |
|
Magna Polonia SA
WAR:06N
|
-0.007x |
|
Aston Bay Holdings Ltd
V:BAY
|
-0.716x |
Annual Cash Flow Conversion Efficiency for Brainstorm Cell Therapeutics Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Brainstorm Cell Therapeutics Inc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see Brainstorm Cell Therapeutics Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.29 Million | $-6.97 Million | 0.678x | -42.13% |
| 2024-12-31 | $-7.76 Million | $-9.09 Million | 1.171x | -72.19% |
| 2023-12-31 | $-4.86 Million | $-20.46 Million | 4.211x | -34.28% |
| 2022-12-31 | $-3.02 Million | $-19.32 Million | 6.408x | +571.89% |
| 2021-12-31 | $19.34 Million | $-26.27 Million | -1.358x | -36.84% |
| 2020-12-31 | $35.46 Million | $-35.19 Million | -0.992x | -207.85% |
| 2019-12-31 | $-12.22 Million | $-11.25 Million | 0.920x | +137.26% |
| 2018-12-31 | $5.02 Million | $-12.39 Million | -2.470x | -514.29% |
| 2017-12-31 | $5.88 Million | $-2.36 Million | -0.402x | +32.04% |
| 2016-12-31 | $9.90 Million | $-5.86 Million | -0.592x | -12.83% |
| 2015-12-31 | $14.13 Million | $-7.41 Million | -0.524x | +22.00% |
| 2014-12-31 | $6.67 Million | $-4.49 Million | -0.672x | +54.58% |
| 2013-12-31 | $2.74 Million | $-4.05 Million | -1.480x | -110.85% |
| 2012-12-31 | $4.15 Million | $-2.92 Million | -0.702x | +53.01% |
| 2011-12-31 | $1.49 Million | $-2.22 Million | -1.494x | -133.14% |
| 2010-12-31 | $-459.00K | $-2.07 Million | 4.508x | +956.02% |
| 2009-12-31 | $-1.74 Million | $-744.00K | 0.427x | -48.90% |
| 2008-12-31 | $-2.08 Million | $-1.73 Million | 0.835x | +14.32% |
| 2007-12-31 | $-2.43 Million | $-1.77 Million | 0.731x | +55.17% |
| 2006-12-31 | $-1.82 Million | $-855.00K | 0.471x | +197.46% |
| 2005-12-31 | $-7.91 Million | $-1.25 Million | 0.158x | +116.45% |
| 2004-12-31 | $704.45K | $-677.84K | -0.962x | -295.97% |
| 2003-12-31 | $-31.44K | $-15.44K | 0.491x | +242.56% |
| 2002-12-31 | $20.36K | $-7.01K | -0.344x | -141.49% |
| 2001-12-31 | $52.16K | $-7.44K | -0.143x | -- |
About Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modul… Read more